Research programme: microbial compounds - Biosortia Pharmaceuticals

Drug Profile

Research programme: microbial compounds - Biosortia Pharmaceuticals

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator Biosortia Pharmaceuticals
  • Developer Biosortia Pharmaceuticals; Nationwide Children's Hospital; The Ohio State University Comprehensive Cancer Center
  • Class Small molecules
  • Mechanism of Action Immunostimulants; Interleukin 17 modulators; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Arthritis; Cancer; Hypercholesterolaemia; Liver cancer; Neuroblastoma; Psoriasis; Seizures

Most Recent Events

  • 06 Jun 2016 Early research in Arthritis in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
  • 06 Jun 2016 Early research in Seizures in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
  • 06 Jun 2016 Early research in Psoriasis in USA (unspecified route) (Biosortia Pharmaceuticals pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top